# 1.0 Submitted By:

Marine Boyajian   
Senior Regulatory Affairs Specialist Beckman Coulter, Inc.   
200 S. Kraemer Blvd., W-110   
Brea, California 92822-8000   
Telephone: (714) 961-6536   
FAX: (714) 961-4234

# 2.0 Date Submitted:

June 11, 2009

3.0 Device Name(s):

3.1 Proprietary Names SYNCHRON® Systems Enzymatic Creatinine (CR-E) Reagent   
3.2 Classification Name Enzymatic Method Creatinine (21 CFR $\ S$ 862.1225)

# 4.0 Predicate Device:

<table><tr><td rowspan=1 colspan=1>Candidate(s)</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Manufacturer&quot;..:..</td><td rowspan=1 colspan=1>DocketNumber</td></tr><tr><td rowspan=1 colspan=1>SYNCHRON SystemsEnzymatic Creatinine (CR-E)Reagent</td><td rowspan=1 colspan=1>SYNCHRON SystemsCreatinine (CR-S) Reagent</td><td rowspan=1 colspan=1>BeckmanCoulter, Inc</td><td rowspan=1 colspan=1>K071283</td></tr></table>

# 5.0 Description:

CR-E reagent is used to measure the creatinine concentration by an enzymatic method. This enzymatic creatinine method utilizes a multi-step approach ending with a photometric end-point reaction.

The SYNCHRON Enzymatic Creatinine (CR-E) Reagent is designed for optimal performance on the SYNCHRON $L X ^ { \mathfrak { B } }$ , UniCel® Dx 600/800, and SYNCHRON $\mathbf { C X } ^ { \mathfrak { B } }$ PRO Clinical Systems. The reagent kit contains two 200-test cartridges that are packaged separately from the associated calibrator.

# 6.0 Intended Use:

CR-E reagent, when used in conjunction with SYNCHRON® Systems, UniCel® DxC Systems and SYNCHRON® Systems AQUA CAL 1 and 2 and SYNCHRON $\mathbf { C X } ^ { \textregistered }$ Calibrator Level 1 and 2, is intended for the quantitative determination of creatinine (CRE) concentration in human serum, plasma or urine (urine is not available on the SYNNCHRON $\cos ^ { \mathfrak { P } }$ PRO Systems).

# Clinical Significance:

Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.

# 7.0 Comparison to Predicate(s):

The following table shows similarities and differences between the candidate Enzymatic Creatinine (CR-E) Reagent and the predicate identified in Section 4.0 of this summary.

<table><tr><td rowspan=5 colspan=1>SYNCHRONSystemsEnzymaticCreatinine(CR-E)Reagent</td><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>Same for the LX/DxC Systems</td></tr><tr><td rowspan=1 colspan=1>Instrument Platforms</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analytical range (Urine)</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=6 colspan=1>SYNCHRONSystemsEnzymaticCreatinine(CR-E)Reagent</td><td rowspan=1 colspan=1>Analytical range(Serum and Plasma)</td><td rowspan=1 colspan=1>CR-E Reagent: 0.2 - 25.0 mg/dLCR-S Reagent: 0.3 - 25.0 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>CR-E Reagent: Plasma and Serum for CX SystemsCR-S Reagent: Plasma, Serum and Urine for CXSystems</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>CR-E Reagent: 10 μl (Serum, Plasma and Urine)Urine sample is diluted by thesystem at ratio of 1:10.CR-S Reagent: 20 μl Serum and Plasma, 3 ul Urine</td></tr><tr><td rowspan=1 colspan=1>Reaction Type(Methodology)</td><td rowspan=1 colspan=1>CR-E Reagent:Enzymatic methodCR-S Reagent:Modified rate Jaffe method</td></tr><tr><td rowspan=1 colspan=1>Calibration Frequency</td><td rowspan=1 colspan=1>CR-E Reagent:Every 14 daysCR-S Reagent:Every 5 days on LX/DxC SystemsEvery 7 days on CX Systems</td></tr><tr><td rowspan=1 colspan=1>Detection Wavelength</td><td rowspan=1 colspan=1>CR-E Reagent: 560 nm (Primary Wavelength)CR-S Reagent: 520 nm (Primary Wavelength)</td></tr></table>

K TimDifferences  Dare a masr

# 8.0 Summary of Performance Data:

The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to chemistry test systems already in commercial distribution. Equivalence is demonstrated through method comparison, stability, linearity, and imprecision experiments.

Serum Method Comparison Summary   

<table><tr><td rowspan=1 colspan=1>Candidate</td><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>SlopeR</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Predicate Method</td></tr><tr><td rowspan=2 colspan=1>EnzymaticCreatinine(CR-E) Reagent</td><td rowspan=1 colspan=1>CX7 PRO</td><td rowspan=1 colspan=1>0.997</td><td rowspan=1 colspan=1>-0.002</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>78</td><td rowspan=2 colspan=1>SYNCHRONSystems Creatinine(CR-S) Reagent</td></tr><tr><td rowspan=1 colspan=1>DxC800</td><td rowspan=1 colspan=1>0.991</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>80</td></tr></table>

Urine Method Comparison Summary   

<table><tr><td rowspan=1 colspan=1>Candidate</td><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R..</td><td rowspan=1 colspan=1>NN</td><td rowspan=1 colspan=1>Predicate Method</td></tr><tr><td rowspan=1 colspan=1>EnzymaticCreatinine(CR-E) Reagent</td><td rowspan=1 colspan=1>DxC800</td><td rowspan=1 colspan=1>0.988</td><td rowspan=1 colspan=1>-3.096</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>SYNCHRONSystems Creatinine(CR-S) Reagent</td></tr></table>

# SYNCHRON Systems Enzymatic Creatinine (CR-E) Reagent Precision Study Results

# Precision Study Results on SYNCHRON CX7 PRO Clinical System

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean,:(mg/dL)</td><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>%C.V.:.</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=5>Within-Run Imprecision</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>.1.4</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>4.16</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>7.69</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=5>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>4.16</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>7.69</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>80</td></tr></table>

# Precision Study Results on UniCel DxC 800 SYNCHRON Clinical System

<table><tr><td rowspan=1 colspan=2>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>%C.V.</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=6>Within-Run Imprecision</td></tr><tr><td rowspan=4 colspan=1>Serum</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>4.09</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>7.56</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=2 colspan=1>Urine</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>66.45</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>146.61</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=6>Total Imprecision</td></tr><tr><td rowspan=4 colspan=1>Serum</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>4.09</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>7.56</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=2 colspan=1>Urine</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>66.45</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>146.61</td><td rowspan=1 colspan=1>1.47</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>80</td></tr></table>

This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.

Beckman Coulter, Inc.   
c/o Ms. Marine Boyajian   
Senior Regulatory Affairs Specialist 200 S Kraemer Blvd., M/S W-110 Brea, CA 92822

AUG 1 4 2009

Re: k091742 Trade Name: Synchron Systems Enzymatic Creatinine (CR-E) Reagent Regulation Number: 21 CFR $\ S 8 6 2 . 1 2 2 5$ Regulation Name: Creatinine Test System Regulatory Class: Class II Product Codes: JFY Dated: June 11, 2009 Received: June 16, 2009

Dear Ms. Boyajian:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's $( \mathrm { O S B ^ { \prime } s } )$ EP Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and·Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

4C.1

Courney C. Harper, Ph.D.   
Acting Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known): 917

Device Name: SYNCHRON® Systems Enzymatic Creatinine (CR-E) Reagent

Indication For Use:

CR-E reagent, when used in conjunction with SYNCHRON® Systems, $\mathsf { U n i C e } | ^ { \otimes } \mathsf { D x } \hat { \mathsf { C } }$ Systems and SYNCHRON® Systems AQUA CAL 1 and 2 and SYNCHRON $\dot { \mathbf { C } } x ^ { \otimes }$ Caibtor Level n inendedor the quantitati determination  creatinie R-)conntrationinhuman plasma or urine (urine is not available on the SYNCHRON $\mathsf { C X } ^ { \circledast }$ PRO Systems).

Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/793e7314f69b844056ab7193ed416f06a67aba5902166687e2d70ec97b3fb239.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety